Leonardo Magneschi, vice president of research & technology development, Ingenza looks at building robust and reliable paths for biologics manufacturing.
The biologics landscape is more diverse than ever, with today’s biopharmaceutical pipeline spanning complex antibody-drug conjugates, novel vaccines and recombinant and fusion proteins. Alongside this growth comes mounting pressure to deliver products faster, more sustainably and at lower cost. For many manufacturers, the path from host selection to full-scale manufacturing is shaped by legacy practices, relying on a narrow set of hosts and following fixed processes that are not tailored to the product. These approaches can introduce inefficiencies, increase the likelihood of technical failure during scale-up and lead to inconsistent product quality that triggers regulatory delays, ultimately extending drug development timelines.